Next Issue
Volume 11, July
Previous Issue
Volume 11, May
 
 

Medicines, Volume 11, Issue 6 (June 2024) – 2 articles

Cover Story (view full-size image): Medicines (ISSN 2305-6320) is an international, peer-reviewed, and open access journal aimed at combining all areas of medical disciplines and subspecialties in one platform. It mainly publishes, but is not limited to, original research papers, case reports, reviews, systematic reviews, brief reports, concepts and opinions on all aspects of basic, clinical, and translational research in relation to human health. The journal will accept manuscripts on medical concepts that include evidence-based medicine and/or alternative medicine. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. Full details must be provided when publishing an experiment so that the results can be reproduced.
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Section
Select all
Export citation of selected articles as:
11 pages, 2055 KiB  
Case Report
An Unusual Case of Immune Complex-Mediated Membranoproliferative Glomerulonephritis as Renal Manifestation of Idiopathic Hypereosinophilic Syndrome: A Case Report and Literature Review
by Michael Cieza-Terrones, José C. De La Flor, Christian Requejo, Daniel Villa, Jacqueline Apaza, Pablo Rodríguez-Doyágüez, Rocío Zamora, Carmen Asato-Higa, David Rivera-Estrella and Antonio Carrasco-Yalán
Medicines 2024, 11(6), 13; https://doi.org/10.3390/medicines11060013 - 2 Jun 2024
Viewed by 589
Abstract
Background: Idiopathic hypereosinophilic syndrome (IHES) is a disorder characterized by abnormal and persistent peripheral blood hypereosinophilia (eosinophil count ≥ 1.5 × 109/L and ≥10% eosinophils) with duration ≥ 6 months, associated organ damage, and/or dysfunction attributable to tissue eosinophilic infiltrate of [...] Read more.
Background: Idiopathic hypereosinophilic syndrome (IHES) is a disorder characterized by abnormal and persistent peripheral blood hypereosinophilia (eosinophil count ≥ 1.5 × 109/L and ≥10% eosinophils) with duration ≥ 6 months, associated organ damage, and/or dysfunction attributable to tissue eosinophilic infiltrate of unknown cause. IHES affects different organs such as the heart, lungs, nervous system, and skin, with renal involvement being rare in this condition. Case Presentation: We present a case of a young patient with IHES and immune complex-mediated membranoproliferative glomerulonephritis with nephrotic syndrome, as a rare renal manifestation. We discuss the clinical, analytical, and histopathologic renal and hematologic features, comparing them with other reported cases in the literature. Full article
(This article belongs to the Section Nephrology and Urology)
Show Figures

Figure 1

10 pages, 1911 KiB  
Article
Incidence and Outcomes of COVID-19 Vaccine Hypersensitivity Reactions and Success of COVID-19 Vaccine Provocation Tests Post Previous COVID-19 Vaccine Hypersensitivity
by Adi Kurniawan, Sukamto Koesnoe, Evy Yunihastuti and Hamzah Shatri
Medicines 2024, 11(6), 12; https://doi.org/10.3390/medicines11060012 - 27 May 2024
Viewed by 599
Abstract
Background: The COVID-19 pandemic has led to high mortality rates. There have been reports of hypersensitivity reactions with mild to severe symptoms. The COVID-19 vaccine provocation test is a vaccination protocol for individuals with a history of hypersensitivity. This study aims to [...] Read more.
Background: The COVID-19 pandemic has led to high mortality rates. There have been reports of hypersensitivity reactions with mild to severe symptoms. The COVID-19 vaccine provocation test is a vaccination protocol for individuals with a history of hypersensitivity. This study aims to determine the benefits of COVID-19 vaccine provocation tests in patients with a history of hypersensitivity reactions to COVID-19 vaccines and its influencing factors. Objective: To determine the incidence, severity, outcome of hypersensitivity reactions, and success of the COVID-19 vaccine provocation test. Methods: A retrospective cohort study was conducted, using subjects taken from medical record data at the RSCM who had received COVID-19 vaccination with a history of hypersensitivity. Data was taken from the COVID-19 vaccination records at the RSCM, BPJS Health Primary Care application. Results: From a total of 29,036 doses of the COVID-19 vaccine, 44 patients experienced hypersensitivity reactions. As many as 38.64% did not continue vaccination, 2.27% experienced mild hypersensitivity, and 59.44% were successfully vaccinated. Conclusions: People with a history of hypersensitivity reactions to COVID-19 vaccines can still receive subsequent COVID-19 vaccinations at healthcare facilities equipped with anaphylaxis kits and immunology allergists. Full article
(This article belongs to the Topic Advances in COVID-19 and Cancer)
Show Figures

Figure 1

Previous Issue
Next Issue
Back to TopTop